M ost tumours are commonly thought to arise from the clonal expansion of a single, initiated cell 1,2 , followed by the generation of distinct subclones that may cooperate to drive tumour growth or progression 3, 4 . Inflammation of the tissue microenvironment leading to 'field cancerization' (for a review, see ref. 5 ) and the discovery of oncogenic point mutations in groups of cells in histologically normal tissue 6, 7 have raised the possibility that multiple cells within a field can participate in the earliest stages of cancer development [8] [9] [10] . Studies using the dimethylbenzanthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis model have also identified stem-cell-like cells driving the distinct clonal growth patterns of benign and malignant tumours 11,12 . Although metastases were once thought to be clonal outgrowths of single disseminated tumour cells, both cell biological [13] [14] [15] [16] and genetic approaches 17,18 have provided evidence for polyclonal contributions. Here, we exploit both multicolour cellular lineage tracing 19 and next-generation sequencing analysis of a mouse model, which recapitulates the mutation burden and heterogeneity seen in human tumours 20-23 , to interrogate clonal dynamics at multiple stages of tumour advancement, from initiation to metastasis.
Results
The Confetti mouse contains a four-colour cassette, which, upon Cre activation, labels each cell with one of four fluorophores: green fluorescent protein (GFP), YFP, RFP or CFP 19 . Topical tamoxifen treatment of K5CreER-Confetti mouse back skin gave rise to durable (up to 18 months) labelling of skin cells with all four colours ( Fig. 1a,b ) with a slight bias in frequency 19 for RFP ( Fig. 1c ). Mice were treated with the carcinogen DMBA 10 days after their final dose of tamoxifen, to allow tamoxifen clearance 24 , and subsequent twice-weekly TPA treatment 25 (Fig. 1d ) generated benign papillomas beginning around 6-8 weeks.
Multiple cell populations contribute to benign papillomas. The majority of papillomas (75%) harvested at 20 weeks post-initiation showed mainly a single colour (the 'bulk colour') but had several, smaller populations of distinct colours also visible. These originated from the base of the tumour and formed 'streaks' up the side of the papilloma ( Fig. 2a ) and were similar to patterns in papillomas observed in carcinogen-treated chimaeric mice 9 . However, early-stage papillomas harvested at 12 weeks after DMBA treatment were single coloured (Fig. 2b,c) , suggesting that the streak patterns developed over time and did not make a substantial contribution to the earliest papilloma growth. Analysis of papillomas harvested between 27 and 49 weeks after DMBA treatment showed patterns identical to those observed at 20 weeks. The increase in the number of 'streaked' papillomas between 12 weeks and both later time points was significant (P = 0.006 and P = 0.00001 between 12 versus 20 weeks and 12 weeks versus terminal papillomas, respectively) ( Fig. 2c ). Streaks comprised on average 6% (ranging from 1% to 17%) of coloured cells in the tumour in both the 20-week and terminal cohorts ( Fig. 2d ). Cross-sectioning of 'streaked' tumours confirmed the whole-mount pattern ( Fig. 2e and Supplementary Fig. 1A,B ), and haematoxylin and eosin (H&E) staining of serial sections revealed no histological differences between cells that belonged to a streak and adjacent cells that did not ( Fig. 2e-h) .
We monitored tumours in two cohorts of control mice (either no tamoxifen, 217 tumours, 10 mice; or no K5CreER, 177 tumours, 7 mice) to determine whether stochastic recombination of the Confetti cassette could affect our observations. In both cohorts, we observed an extremely low level of Confetti leakiness. In a small number of papillomas-four papillomas from the 'no tamoxifen' cohort (2.3%) and ten papillomas from the 'no K5CreER' cohort (4.6%)-one or two individual spots of colour were observed. These were significantly smaller in size than the 'streaks' described above (< 15 cells) and lacked any trends in localization. Furthermore, no leakiness was observed in carcinomas or metastases from either cohort (0 out of 11 and 0 out of 9 carcinomas and 0 out of 8 and 0 out of 9 metastases in the 'no tamoxifen' and the 'no K5CreER' cohorts, respectively).
Minor cell populations are recruited cells and papillomas are monoclonal in origin.
To address the question of whether the Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma evolution from initiation to metastasis Melissa Q. Reeves *, Eve Kandyba, Sophie Harris, Reyno Del Rosario and Allan Balmain * Tumour cells are subjected to evolutionary selection pressures during progression from initiation to metastasis. We analysed the clonal evolution of squamous skin carcinomas induced by DMBA/TPA treatment using the K5CreER-Confetti mouse and stage-specific lineage tracing. We show that benign tumours are polyclonal, but only one population contains the Hras driver mutation. Thus, benign papillomas are monoclonal in origin but recruit neighbouring epithelial cells during growth. Papillomas that never progress to malignancy retain several distinct clones, whereas progression to carcinoma is associated with a clonal sweep. Newly generated clones within carcinomas demonstrate intratumoural invasion and clonal intermixing, often giving rise to metastases containing two or more distinct clones derived from the matched primary tumour. These data demonstrate that late-stage tumour progression and dissemination are governed by evolutionary selection pressures that operate at a multicellular level and, therefore, differ from the clonal events that drive initiation and the benign-malignant transition.
'streaks' that develop during papilloma growth were genetically initiated cells, four multicoloured tumours were analysed by fluorescence-activated cell sorting (FACS) ( Fig. 3a and Supplementary  Fig. 1C ), followed by Sanger sequencing of Hras in 'bulk' and 'streak' cells from each papilloma 22, 26 . We found the expected Hras Q61L mutation in the bulk population of all four tumours; however, all of the streak populations were wild type for Hras by Sanger sequencing ( Fig. 3b ).
By sequencing whole exomes ( Fig. 3b-h) , we found that the streaks carried fewer total mutations (4.8 versus 13.3 mutations per Mb in the bulk population) ( Fig. 3c ). However, the bulk populations carried a distinct DMBA-specific A > T mutation signature associated with the mis-repair of adducts formed with adenosine residues in DNA 27 and consistent with previous sequencing of tumours from this model 22, 28 . Streak populations carried almost no A > T mutations and instead had a mutation signature that primarily comprised G > T mutations ( Fig. 3d ), possibly due to oxidative stress induced by the tumour promoter TPA 22 . In support of this, G > T mutations in these populations showed no strand bias, consistent with being induced by reactive oxygen species, and in contrast to the carcinogen-induced A > T mutations ( Fig. 3f ).
Furthermore, although the bulk population carried gains of chromosome 7, effectively duplicating the mutant copy of the Hras gene located on this chromosome 22, 29 , the copy number profiles of the streak populations were completely silent (Fig. 3e) . The mutation and copy number data together indicate that these streaks are derived from normal, neighbouring K5+ keratinocytes (as evidenced by the Confetti labelling), which were co-opted to grow and proliferate abnormally in the tumour.
Although the streak populations lacked the common Hras driver mutation and showed no sign of genomic instability, both the bulk and the streak populations alike carried potentially oncogenic mutations [30] [31] [32] (Fig. 3g and Supplementary Tables 1 and 2 ). In the bulk populations, in addition to Hras mutations, we found mutations in Trp53, Ep300, Fat1 and Ncor1, all of which have been previously reported to be recurrently mutated in DMBA-induced tumours 22, 28 (Fig. 3g and Supplementary Table 1 ). In the streak populations, we detected two Notch mutations, Notch1 D545H and Notch2 P863H ( Fig. 3g and Supplementary Table 2 ), both of which are in amino-terminal epidermal growth factor (EGF)-like repeat domains that are responsible for Ca 2+ binding. Interestingly, Notch mutations in this specific region are associated with squamous tumour development 31 and have also been previously detected in DMBA-induced tumours 22, 28 . Similar mutations in Notch have been found in histologically normal microdissected areas of human skin and have been proposed to confer a selective growth advantage 7 . We also detected a Pten M1R mutation, which was expected to result in a loss of translation of the tumour suppressor Pten, and a stop-gain mutation in Map3k1 (G1371X), which confers an early truncation in the kinase domain. Missense mutations and deletions Supplementary Table 3 for statistics source data. d, A schematic of the tumorigenesis strategy. K5CreER-Confetti mice were treated with 4 doses of tamoxifen to activate Confetti labelling and then treated with the carcinogen DMBA 10 days after the final tamoxifen dose, followed by biweekly treatments with the tumour promoter TPA. Dozens of benign papillomas emerge beginning at 6-8 weeks, a subset of which progresses to carcinomas. Carcinomas are surgically resected when they reach 1 cm in diameter, and mice go on to develop metastatic disease.
of MAP3K1 have been reported in numerous tumour types, including breast and prostate cancers 33 . These mutations together suggest that the streak populations, despite lacking an initiating Hras mutation, are subject to similar selection pressures as the bulk tumour.
We examined the variant allele frequency (VAF) of mutations in the bulk and streak populations to assess their respective clonalities. The average VAFs in the bulk populations were significantly higher than those in their respective streak counterparts ( Fig. 3h , on The cells belonging to bulk CFP+ and to streak RFP+ and YFP+ populations are pathologically indistinguishable. See Supplementary Table 3 for statistics source data.
average, VAF = 0.36 in the bulk versus 0.19 in the streak populations, P < 2.2 × 10 -16 ). This is consistent with the bulk population being a single population that contains many clonal mutations (as well as some subclonal mutations acquired during continued tumour growth), whereas the sorted streak populations each comprised multiple populations (for example, multiple streaks of the same colour; see Fig. 2a ). Finally, we asked whether the presence of monocolour patches in the interfollicular epidermis at the time of initiation could have masked polyclonal contributions to the 'bulk' population of these tumours. Given the relatively small patch size (average 6-7 cells in cross-section) and the large number of papillomas collected (380 papillomas), such masking was statistically improbable, as a tumour lacking an obvious 'bulk' colour was never observed. We further looked at the mutant allele fraction of DMBAassociated T > A mutations in the bulk population of each tumour sequenced, which are expected to have a mutant allele fraction of around 0.5 in a clonal population. The mean mutant allele fraction for T > A mutations was 0.43, with a unimodal distribution, in agreement with the 'bulk' colour population comprising a single initiated clone and potentially a small number of cells belonging to matching coloured streaks.
Non-progressing papillomas harbour multiple equipotent clones, but a single clone drives progression to malignancy.
To investigate the cellular dynamics of malignant progression, we next activated Confetti labelling in established early papillomas. DMBA/ TPA-treated K5CreER-Confetti mice were given two doses of topical tamoxifen 8 weeks after DMBA treatment, when papillomas were typically 0.5-2 mm in size ( Fig. 4a ). This resulted in widespread labelling of papillomas with all four Confetti colours ( Fig. 4b ), activating fluorescence in approximately 45% of tumour cells, as well as labelling of adjacent skin. We monitored these mice over a period of 6-7 months after labelling, to compare clonal dynamics in papillomas that never underwent malignant progression to those that progressed. In nonprogressing papillomas, typically several large monocolour clones emerged ( Fig. 4c -e) and persisted through to the time of death 6 months later. In these non-progressing papillomas, no significant clone intermixing occurred ( Fig. 4f ,g and Supplementary Fig. 2A -D) and no single dominant clone emerged within the tumour. Furthermore, neighbouring clones were histologically indistinguishable from one another (Supplementary Fig. 2A 
By contrast, a different pattern was seen in carcinomas that developed from papillomas in this same cohort of mice. Carcinomas, which were surgically resected when they reached 1 cm in diameter, were all composed of a single-colour clone ( Fig. 4h ,i). Approximately half (6 out of 13) were entirely coloured (3 RFP, 2 YFP and 1 CFP), whereas the others were entirely uncoloured. Single-colour patterns were confirmed by FACS for 11 out of 13 tumours (the remaining 2 carcinomas were not sorted) and by sectioning. To assess the significance of this, we compared this single-colour pattern in carcinomas with the number of visible coloured lobes in papillomas that were age matched to a carcinoma or obtained at death. Whereas carcinomas comprised only one colour, papillomas contained on average 2.5 distinctly coloured, externally visible lobes (P = 0.0003). This number is probably an underestimate, as only the externally visible papilloma lobes were scored on whole-mount tumours. For example, two such distinct lobes are seen in the right-hand whole-mount tumour in Fig. 4d ; however, cross-sectioning of this tumour shown in Fig. 4e reveals at least three additional lobes (for example, a small CFP lobe in the lower right, a small RFP lobe in the middle and a GFP lobe at the top that was previously indistinguishable from the large YFP lobe).
It should be noted that, in assessing carcinoma colour, we focused on the tumour core. It is common for a carcinoma to grow partially beneath the skin, and so at the periphery, it is not unusual to see hair follicles and an interfollicular epidermis that differ in histology as well as colour pattern from the tumour ( Supplementary Fig. 2E ), which we excluded from our analysis. Furthermore, although the streaks observed in papillomas could be detected in these carcinomas as well as in carcinomas that developed from mice in the skin-labelling experiment described above, they were restricted to the periphery of the tumour (Fig. 4j ). This suggests that, whatever role these genetically more 'normal' streaks might have in papilloma development, they are not essential to the tumour after progression to malignancy.
We conclude that, although non-progressing premalignant tumours retain distinct clones, progression to malignancy is characterized by the sweep of a single clone, which dominates in malignant carcinomas.
Intratumoural invasion and clonal intermixing are features of carcinoma progression.
To investigate clonal diversity and behaviour during the benign-malignant transition itself, we next labelled papillomas at 24 weeks, which is closer to the time of progression ( Fig. 5a,b ). As in the 8-week labelling experiment, papillomas that did not progress to carcinomas over the following 6 months exhibited multiple coloured regions. However, carcinomas that emerged in this experiment showed a range of labelling patterns, falling into three categories: multicoloured, speckled and single coloured. These patterns seemed to correlate with the latency between tamoxifen labelling and carcinoma appearance and harvest ( Fig. 5c ), suggesting that we were able to observe snapshots of tumour dynamics at distinct points in time during progression.
In five carcinomas harvested between 2 and 6 weeks after labelling, we observed numerous distinctly coloured clones growing side by side ( Fig. 5d -g and Supplementary Fig. 3 ). We observed that, at the intersection of coloured subclones, mixing of cell populations could be seen ( Fig. 5f and Supplementary Fig. 4A ) and that subclones could not be distinguished from each other by H&E staining (Fig. 5e,g) . Interestingly, distinct subclones displayed differential proliferative capacities, as evidenced by the levels of Ki67 staining ( Supplementary Fig. 3 ). Whether the more proliferative subclone (or subclones) would eventually come to dominate the carcinoma is unclear.
In contrast to this highly multicolour pattern in carcinomas that emerged shortly after labelling, carcinomas harvested 5-10 weeks after tamoxifen treatment typically exhibited a single dominant colour clone, but also contained 'speckled' patches in which cells of a distinct colour were locally intermixed with the contiguous, dominant colour clone ( Fig. 6a-d and Supplementary Fig. 4B ). Carcinomas could have multiple such localized speckled patches of distinct colours (Fig. 6c ). These speckles displayed a pattern reminiscent of the border between two clones in the multicolour carcinoma ( Fig. 5f ) and were indistinguishable by H&E staining (Fig. 6e ). Neither the speckled cells nor the speckled regions showed particular co-localization with microenvironmental structures, including lymphatic vessels (stained for with LYVE-1) or blood vessels (CD31) (Fig. 6f,g and Supplementary Fig. 5A ). Squamous tumour speckles were positive for K14 ( Supplementary Fig. 5B ), which is consistent with this pattern being the result of intermixing of two tumour clones, rather than aberrant Confetti activation in a stromal or other cell type.
To address the possibility that the speckled subclones were the remnants of clones that were being outcompeted by the dominant clone, we quantified localized Ki67 levels in both populations. These data revealed that the speckled subclones were nearly always growing at the same rate or faster than the dominant clone with which they were locally intermixed ( Fig. 6h ). These observations, along with proliferation data from the multicolour tumours, indicate that carcinoma growth is driven by several, intermixed subclones and, furthermore, that these subclones emerge after the Gains of chromosome 7, on which Hras is located, were observed in all four bulk populations; no copy number alterations were observed in streak populations. f, The frequency of each base on the coding strand that is mutated for T > A (A > T) and G > T (C > A) mutations (n = 9 samples). T > A (A > T) mutations showed a bias for 'A' on the coding strand at the mutated site; G > T (C > A) mutations showed no bias. Bar graphs show the mean ± s.e.m. NS, not significant. g, A comparison of cancer-associated mutations in bulk and streak samples (right panel, each column represents one sample) with the frequency of mutations in these genes in a previously published cohort 23 (right panel). The VAF is colour-coded dark green for mutations that are present in > 20% of reads and light green for < 20% of reads. Note that, although a mutation in Hras was detected in a single streak sample, it was present at a low allele fraction. h, VAFs of mutations in bulk and streak samples (n = 573, 181, 932, 322, 339, 107, 135, 845 and 56 mutations, left to right). Samples are organized by tumour of origin; in each case, the VAFs in the bulk population are higher, consistent with a population of clonal origin. Box plots extend the first to the third quartile, the median is marked by a crossbar and P values are based on a two-sided Student's t-test. See Supplementary Table 3 for source data.
clonal sweep associated with progression to malignancy ( Fig. 6i,j) . This pattern is distinct from the equipotent clones observed in papillomas ( Fig. 6i,j) , which tended to remain localized to specific lobes with clear boundaries ( Fig. 4e-g to distant sites. For mice in all Confetti-labelling cohorts, the primary carcinomas were surgically removed when they reached 1 cm in diameter, enabling prolonged survival of the animals and subsequent harvesting of any metastases that developed. On average, mice received their first surgery 32 weeks after DMBA treatment (range: 26-43 weeks) and survived an additional 6 weeks (range: 2-16 weeks). We collected a total of 40 metastases from 14 mice labelled at either of the two earlier time points (labelling of pre-initiation skin or 8-week papillomas), and these were uniformly single coloured (Fig. 7a,b) , consistent with the clonal patterns in carcinomas in these mice. Furthermore, in the majority of mice (9 out of 12 (75%)) in which multiple metastases were collected, metastases to distinct locations were the same colour as one another, with as many as 8 matching coloured metastases found in one mouse (Fig. 7a,b ). This is in agreement with previously published phylogenetic trees from this model demonstrating that most commonly, all metastases arise from the same primary tumour 22 . This previous work 23 suggested that metastatic dissemination occurs before surgical resection of the primary tumour and, in some cases, at relatively early stages of tumour development, as shown by the existence of many 'private' mutations that are unshared between primary carcinomas and their matched metastases. Our data showing that metastases from animals with early Confetti activation invariably are composed of one single colour could either mean that metastasis is a clonal event or that polyclonal dissemination took place after an early clonal sweep, followed by the generation of distinct genetic subclones of the same colour.
To address these possible scenarios, we investigated the clonality of the metastases in mice in which Confetti labelling occurred at 24 weeks-the only cohort bearing multicolour primary carcinomas. We collected 12 metastases from 5 mice and observed metastases composed of multiple distinctly coloured cellular populations in 3 of the 5 mice ( Fig. 7c ). Although this cohort was small, the finding of multicoloured metastases in 3 mice (60%) was significant compared to 0 out of 14 mice (0%) in the earlier cohorts (P = 0.010, Fisher's exact test). In one case, we observed three multicolour metastases in the same animal, with two lymph node metastases and a lung metastasis all comprising a mix of RFP and YFP cells (Fig. 7c ).
For two additional cases of multicolour metastases, we used exome sequencing to ask whether the distinct cell populations in each metastasis were from the same primary tumour. For the first case, we sequenced a lymph node metastasis in which K14+ cells (that is, tumour cells) were 75% uncoloured and 25% GFP+ and intermixed in a speckling pattern (Fig. 7d) . The lymph node metastasis shared 350 mutations with one of three primary carcinomas in the mouse (carcinoma A) ( Fig. 7e,f) . We could not initially be certain whether these 350 mutations were present in both the uncoloured and GFP+ cells in the metastasis, so we asked whether mutations in the other carcinomas (carcinoma B and carcinoma C; Fig. 7e ) were present at low levels in the metastasis, particularly in loci that are well covered by sequencing reads (> 50× ), and found that they The cells belonging to the uncoloured YFP+ and GFP+ clones are indistinguishable by H&E staining. f,g, Speckled carcinomas stained for LYVE-1 (f) and CD31 (g) (four tumours stained, five sections each). No trends in localization were observed between speckles and blood vessels (CD31) or lymphatic vessels (LYVE-1). h, The relative levels of Ki67+ staining between dominant and speckle populations in selected local regions, representing tumours from multiple mice (counts based on n = 6, 3, 6, 3 and 3 sections for tumours, left to right). Bar graphs show the mean ± s.e.m. See Supplementary Table 3 for statistics source data. i, Model for clonal evolution of a terminally benign papilloma. Tumour arises from a single cell but incorporates distinct, genetically normal external populations, typically in a streaking pattern. A small number of subclones maintain long-term tumour growth, and these are frequently localized to distinct spatial locations with limited intermixing. j, Clonal evolution of a progressing tumour. Early evolution mirrors that of a terminally benign papilloma, however a clonal sweep occurs at the time of progression. Following this sweep, multiple subclones of the progressing clone contribute to growth of the malignant tumour as well as to metastasis, and frequently intermix with one another. Fig. 7 | Evidence for polyclonal seeding of metastasis. a,b , Metastases to the chest wall (a) and the lung (b) from a mouse in which skin was labelled pre-initiation (the experimental design is described in Fig. 1d; 10 mice) , viewed from a fluorescent dissecting microscope. All metastases are from the same mouse and are uniformly red (RFP+ ). The same pattern was observed in mice in which papillomas were labelled at 8 weeks (4 mice). c, Lung metastasis from a mouse in which papillomas were labelled at 24 weeks (the experimental design is described in Fig. 5a ; 5 mice), viewed from a fluorescent dissecting microscope, containing both red (RFP+ ) and green (YFP+ ) cells. The lung is outlined with a dashed line. d, A cross-section of a lymph node metastasis from a second mouse in which papillomas were labelled at 24 weeks (the experimental design is described in Fig. 5a were not. We also examined mutations in the metastasis that were not shared with carcinoma A for contributions from an unidentified primary tumour, which would have contributed its own fingerprint of DMBA-induced T > A signature mutations 22 -however, we found only four T > A mutations in the metastasis that were not present in carcinoma A. We conclude that no evidence exists in the sequencing data that would support the possibility that the uncoloured cells and GFP+ cells in this metastasis originated from different primary tumours, but rather, both cell populations arose from carcinoma A.
Interestingly, carcinoma A was a predominantly uncoloured tumour with a significant GFP+ speckle region, visible in the middle and right of the tumour cross-section (Fig. 7f ). Both the uncoloured cells and the GFP+ cells in this region were highly proliferative (Fig. 7g,h; 62% and 56% Ki67+ cells, respectively) . This carcinoma also contained YFP+ and RFP+ speckle regions, visible at the left side of the cross-section (Fig. 7f) . However despite the presence of these YFP+ and RFP+ cells in the primary tumour, apparently only the GFP+ and the uncoloured populations contributed to metastasis.
We performed exome sequencing on a second case of multicolour metastasis: a lymph node metastasis from another mouse that contained both RFP+ and uncoloured K14+ tumour cells ( Supplementary Fig. 6A ). In this case, we sorted the RFP+ and the uncoloured populations by FACS ( Supplementary Fig. 6B ), then sequenced and again confirmed that they originated from the same primary tumour on the basis of shared mutations and shared copy number alterations ( Supplementary Fig. 6C ).
We conclude that metastases, in contrast to the earlier stages of tumour progression, do not arise from a single cell within the primary tumour that has acquired metastatic properties, but rather, that multiple cells within progressed lesions have the capacity to disseminate and seed at distant sites. Thus, these data agree with a polyclonal model of metastatic dissemination. Notably, the distinct clones seen in metastases showed a pattern of intimate intermixing (Fig. 7d ) that was a feature of progression to carcinoma.
Discussion
We have exploited multicolour lineage tracing using the Confetti mouse to investigate the clonal dynamics that govern each stage of tumour progression from initiation to metastasis. Others had previously used mouse models to demonstrate that papillomas were possibly polyclonal in origin 9 or that DMBA-initiated papillomas can contain cells that do not harbour the known initiating Hras Q61L mutation 10 . Our data demonstrate that these cells were not co-initiators of the papilloma, as they lacked the genetic changes, including the initiating Hras mutation, trisomy of chromosome 7 and the DMBA mutation signature, that are characteristic of papillomas. This implies that the presence of multiple cellular populations in the tumour is not in itself evidence of true polyclonal initiation, although it has historically been interpreted as such in studies of both mouse models and human tumours 34, 35 . The streaks we observed were reminiscent of a similar radial streaking pattern displayed by lineage tracing of Krt15+ hair follicle bulge stem cells during wound healing 36 , calling to mind the analogy of a tumour to a wound that never heals 37 . However, their presence seems to not be necessary for progression to carcinoma, as they become increasingly marginalized during malignant conversion. Interestingly, Krt15+ stem cells also make only a transient contribution to normal healing wounds 36, 38 .
Labelling of established papillomas at 8 or 24 weeks after initiation allowed us to detect distinct patterns of clonal evolution during progression to malignancy. Papillomas that had not progressed after 6 months consisted of 2-4 distinct coloured clones (Fig. 6i ), which could have arisen from rare papilloma stem cells 11, 12 . However, progression to carcinoma occurred after a clonal sweep, resulting in the emergence of one dominant clone. Labelling papillomas at 24 weeks showed that most carcinomas that emerged within the next 10 weeks contained two or more intermixed, proliferating cellular populations (Fig. 6j) , which may represent functionally distinct cells that cooperate, through paracrine or juxtacrine interactions 3, 4 . Similar processes may contribute to tumour dissemination, as multiple carcinoma clones frequently participated in metastasis. Such clonal cooperativity has been observed in small-cell lung cancer cell lines in vitro and in vivo 3 , in a model of mouse mammary tumour virus-driven breast cancer 4 and even during bacterial evolution over thousands of generations in culture 39 . Given the importance of cellular and genetic heterogeneity in human cancer prognosis 40 , further studies of this symbiosis may foster the development of new approaches to inhibit these interactions for cancer therapy.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0109-0.
Mice and carcinogenesis. To induce tumours, male and female K5CreER-Confetti FVB/N mice were shaved and treated with 25 mg DMBA dissolved in 200 µ l acetone either 10 days after the final dose of tamoxifen (skin activation experiment) or at 8 weeks of age (tumour activation experiments). Mice subsequently received TPA (200 µ l of a 10 -4 M solution in acetone) two times a week for 20 weeks, following established chemical carcinogenesis protocol 25 . Carcinomas were surgically resected when they reached a size of > 1 cm in longest diameter, and mice given 0.24 ml meloxicam (5 mg ml -1 solution, Boehringer Ingelheim) for recovery. Mice were killed when the disease progressed, per animal care requirements. At death, papillomas and carcinomas were removed from the skin and all internal tumours were resected. All animal experiments were approved by the University of California San Francisco Laboratory Animal Resource Center (protocol approval no. AN159869). This work complies with all the relevant ethical regulations regarding animal research.
Confetti labelling. Tamoxifen (Sigma) was dissolved overnight in sunflower seed oil at a concentration of 10 mg ml -1 . Mice were treated with 400 µ l (4 mg) per dose, applied to the back skin topically, and were shaved the day prior to the first treatment. For the skin activation experiment, mice were given 4 doses every other day for a total of 16 mg. For the tumour activation experiments, mice were given 2 doses for a total of 8 mg, spaced 2 days apart, at either 8 or 24 weeks. Tissue harvesting. Skin, tumour and metastatic tissues harvested for sectioning were kept at 4 °C in 10% formalin overnight, in a gradient of 15%/20%/30% sucrose on the second day, in 30% sucrose overnight on the second night and then embedded in optimal cutting temperature (OCT; Tissue-Tek, Sakura) and stored at -80 °C until sectioning.
Digestion for FACS.
For tumours that were FACS sorted, a piece of the tumour was first removed for embedding in OCT and imaging. For carcinomas, skin tissue along the edge of the carcinoma was also removed. Tumours were then finely chopped, washed with PBS, digested in 4 mg ml -1 collagenase A (Sigma-Aldrich) for 1 h at 37 °C, and then resuspended in 0.25% trypsin-EDTA (Gibco Life Technologies) and incubated on a shaker at 37 °C for 1 h. Trypsin was neutralized with an equal volume of FBS, and digested tumour was filtered through a 40-µ m filter, pelleted and resuspended in FACS buffer (2% FBS) for sorting.
Quantification of Confetti labelling.
To quantify Confetti activation in the skin, a strip of skin oriented along the spine was collected for 5 mice 10 days after the final dose of tamoxifen, for example, the day that DMBA treatment would have begun. To quantify Confetti activation in tumours, papillomas were surgically removed 3 days after the final dose of tamoxifen. Tissues were harvested and embedded in OCT as described above, and 5-µ m sections were taken for quantification. For each sample, a minimum of 10 images were taken at × 40 with a 6D Nikon microscope, and nuclei and coloured cells of each colour were manually counted in ImageJ.
Quantification of multicolour papillomas. At death, the back skin was removed intact from mice and imaged whole on an MVX10 fluorescent stereoscope, which could distinguish RFP, CFP and YFP/GFP. YFP and GFP were not distinguishable from each other under this microscope. Tumours on each back skin were counted and the colour (or colours) was recorded. For statistical calculations (for example, Fig. 2c ), mice that had fewer than three papillomas were excluded as they did not provide sufficient data (this led to the exclusion of two mice).
Quantification of streak populations.
To calculate the percentage of coloured cells comprised by streak populations, the number of sorted RFP, CFP and YFP/GFP cells was used. Owing to the weakness of the CFP fluorophore, bulk CFP tumours (CFP confirmed by sectioning) were widely variable as to the number of CFP+ cells that could be collected; to reduce the large amount of noise introduced by this, we used only bulk RFP, bulk YFP and bulk GFP tumours for these calculations.
Nucleic acid extraction. DNA was extracted from tumours using Qiagen DNeasy
Blood & Tissue Kit, following the manufacturer's instructions. In cases where DNA was extracted after FACS sorting, the protocol was modified as follows to improve yield: (1) after sorting, the FACS collection tube was spun down at 3,000 r.p.m. for 10 min and cells were resuspended in 200 µ l PBS before the initial lysis step;
(2) the wash step with the buffer AW2 was done twice. The DNA concentration and quality were determined by Nanodrop spectrophotometry.
Sanger sequencing of the Hras locus. The Hras locus containing codon 61 was PCR amplified using the primer pair AAGCCTGTTGTTTTGCAGGA (forward) and GGTGGCTCACCTGTACTGATG (reverse). The PCR product was purified using exonuclease I (USB) and shrimp alkaline phosphatase (Affymetrix), and Sanger sequencing was performed using the forward primer listed above by MCLAB. Images were taken using FinchTV.
Exome sequencing. DNA samples were submitted to Otogenetics Corporation for mouse exome capture and sequencing. Illumina libraries were made from qualified fragmented guide DNA using the SPRIworks HT Reagent Kit (Beckman Coulter), and the resulting libraries were subjected to exome enrichment using SureSelectXT Mouse All Exon (Agilent) following the manufacturer's instructions. Enriched libraries were tested for enrichment by qPCR and for size distribution and concentration by the Agilent Bioanalyzer 2100. The samples were then sequenced on an Illumina HiSeq2500 using Rapid v2 SBS chemistry, which generated pairedend reads of 106 nucleotides.
Sequence alignment, processing and quality control. Reads were mapped to the GRCm38/mm10 version of the Mus musculus genome using BWA (version 0.7.12) 41 with default parameters. The Picard MarkDuplicates module was used to remove duplicates from the data (version 1.131; http://broadinstitute.github. io/picard). The Genome Analysis Tool Kit (GATK-Lite, version 2.3-9) 42 module IndelRealigner and BaseRecalibrator were used to preprocess the alignments. During base quality recalibration, Single Nucleotide Polymorphism Database (dbSNP) variants were used as known sites, according to GATK Best Practices recommendations 43 . Finally, alignment and coverage metrics were collected using Picard. We sequenced an average of 42 million unique reads per sample. Targeted bases were sequenced to a mean depth of 50, and > 75% of targeted bases were sequenced to 20× coverage or greater.
Variant calling. Single-nucleotide variants were called using the somatic variant detection program MuTect (version 1.1.7) 44 . Each tumour was called against its matched normal tissue (tail) and calls were filtered against a database of known Mus musculus germline single-nucleotide polymorphisms available at ftp.ncbi. nih.gov/snp/organisms/mouse_10090/VCF/genotype, as well as against a panel of normal tails from this experiment. Results were further filtered to calls with a minimum read depth of 10 at the locus for both tumour and matched-normal reads, and to calls where at least one alternate read had a mapping quality score of ≥ 60. Variants were annotated using Annovar (downloaded on the 4 February 2016) 45 , and these annotations were used as the basis for assessing exonic variants as synonymous, non-synonymous, stop-gain or stop-loss. Mutations in cancerassociated genes were identified, where cancer-associated genes were considered to be those commonly mutated in head and neck squamous cell carcinoma 31 or in cutaneous skin squamous cell carcinoma 32 in The Cancer Genome Atlas data or in a previously published list of cancer driver genes 30 .
Copy number calling was done with CNVkit 46 , and the tumour copy number status was called against a panel of normal tails from the same sequencing batch.
Mutation context. For the mutation spectrum analysis, single-nucleotide variants in all tumours were annotated with 1 of 96 possible trinucleotide context substitutions (6 types of substitutions × 4 possible flanking 5′ bases × 4 possible flanking 3′ bases), using the MuTect output, and the counts of each mutation context were summed.
Phylogenies.
To build phylogenetic trees, absolute distance matrices were calculated based on the presence of mutations in the sample, based on filtered MuTect calls. Rooted trees were built with the use of the Analyses of Phylogenetics and Evolution (APE) package and the Manhattan calculation method implemented in R version 2.15. Relationships between metastases and primary tumours were determined on the basis of shared mutations.
Quantification of coloured lobes in papillomas labelled at 8 weeks. Papillomas were imaged whole on an MVX10 fluorescent stereoscope. Images were taken to record observations and these whole-tumour images were used to count the number of distinctly coloured lobes on each tumour. It was possible to identify RFP, CFP, YFP/GFP and uncoloured lobes; however, YFP and GFP could not be distinguished from each other using this microscope. Selected tumours from this cohort were also embedded in OCT as described above, sectioned and 5-µ m sections were imaged with a Nikon 6D microscope to confirm lobe quantifications done with the whole-mount tumour. Results from imaging these sections correlated well with the whole-mount observations. For statistical analysis, when comparing the number of coloured lobes in papillomas and carcinomas, we excluded fully uncoloured papillomas and carcinomas because it is impossible to distinguish a monoclonal tumour from a poorly labelled polyclonal tumour with multiple uncoloured subclones; thus, we included only tumours where at least one Confetti colour was visible in the analysis.
Classification of labelling pattern in tumours labelled at 24 weeks.
For carcinomas harvested in the 24-week labelling experiment, all carcinomas were embedded in OCT as described above, sectioned and imaged with a Nikon 6D microscope to classify their labelling pattern. At least two distinct pieces of each carcinoma were used and at least 3 serial sections were taken ≥ 100 µ m apart. Tumours that were classified as multicolour contained large, contiguous patches of at least two of the four Confetti colours. Tumours that were classified as speckled showed one or more 'speckle' populations of cells that were a distinct colour from the surrounding tumour cells, and which formed localized patches of noncontiguous cells (in contrast to the contiguous patches observed in multicolour tumours) and could be identified in at least three serial sections from the tumour.
Tumours that were classified as single colour contained only one colour population of cells in the tumour, excluding hair follicles and the interfollicular epidermis that were sometimes present at the edge of the tumour.
Immunofluorescent staining. Slides with 5-µ m tumour sections were brought to room temperature, post-fixed in 4% paraformaldehyde for 8 min and washed in PBS for 5 min. For Ki67 staining, slides were blocked in 5% goat serum/0.3% Triton X-100 for 1 h. The Ki67 antibody (9129, Cell Signaling) was used at a concentration of 1:300 in 2% goat serum/0.3% Triton X-100 and left on slides overnight. Slides were washed three times in PBS and incubated with goat anti-rabbit Alexa Fluor 647 (A21246, Thermo Fisher) secondary antibody at a concentration of 1:200 for 90 min and then washed two times with PBD (PBS with 0.1% Tween-20) followed by PBS. For K14, LYVE-1 and CD31 staining, slides were blocked in 10% donkey serum/0.1% Triton X-100 for 15 min. The K14 antibody (905301, Biolegend) was used at a concentration of 1:2,000 and allowed to incubate on slides for 2 h. For lymphatic vessel staining, the LYVE-1 antibody (ab14917, Abcam) was used at a concentration of 1:100 and allowed to incubate on slides for 2 h. For blood vessel staining, the CD31 antibody (ab28364, Abcam) was used at a concentration of 1:300 and allowed to incubate on slides for 2 h. For K14, LYVE-1 and CD31 staining, the secondary antibody of either donkey anti-rabbit Alexa Fluor 594 (A21207, Thermo Fisher) or Alexa Fluor 488 (A21206, Thermo Fisher) was selected to avoid interference with Confetti colours in relevant samples, and slides were incubated with the secondary antibody at a concentration of 1:500 for 1 h and washed three times with PBS.
Quantification of Ki67.
Tumour sections stained for Ki67 were imaged with a Nikon 6D microscope. Quantification was based on manual counts using ImageJ of at least 3 images taken at × 40 magnification, where individual cells could be identified and classified based on both the presence or the absence of Ki67 and Confetti-labelling colour.
Statistics and reproducibility. Statistics and P values throughout the manuscript were calculated with Student's two-tailed t-test, using R (version 3.2.3). For Figs. 2c,d, 3h , 5c,m and 6g, two-sample t-tests were performed to calculate the difference between two distributions as shown. For Fig. 3f , a one-sample t-test was performed for each sample to evaluate the null hypothesis of the mean equal to 0.5 (that is, even distribution of the mutation between the strands). The skin-labelling experiment was performed in 8 mice for the 12-week observation, 4 mice for the 20-week observation and 9 mice for the observation of terminal disease, with reproducible results between all mice in each cohort. The 8-week labelling experiment was performed in 4 mice, divided into 2 cohorts, with reproducible results between all mice. The 24-week labelling experiment was performed in 5 mice, divided into 3 cohorts, with reproducible results between all mice.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. Data availability. Exome sequence data that support the findings of this study have been deposited in the European Nucleotide Archive under accession number ERP107810. Source data for Figs. 1c, 2c,d, 3c ,d,f, 5c, 6h and 7g have been provided as Supplementary Table 3 . All other data supporting the findings of this study are available from the corresponding author on reasonable request. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
nature research | reporting summary
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. Validation All primary antibodies validated by manufacturer (Cell Signaling, Biolegened, Abcam) to be reactive with mouse and suitable for immunofluoresence/immunohistochemistry. All secondary antibodies validated by manufacturer (Thermofisher) to react with target species (rabbit) and to be suitable for immunofluoresence.
Research animals
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Animals/animal-derived materials All animal experiments were approved by the University of California San Francisco Laboratory Animal Resource Center. Male and female K5CreER x Confetti FVB/N mice were randomly assigned to all cohorts, and all cohorts contained male and female mice in approximately equal proportions; with the exception of the skin-labeling terminal-papilloma cohort which was by chance biased toward female mice (75% female). Mice were entered into experiments at 8 weeks of age, at which point they either received tamoxifen (skin labeling cohort), followed by DMBA/TPA; or DMBA (8-week and 24week labeling cohorts) followed by TPA and tamoxifen at the relevant labeling point (8 or 24 weeks). The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
Method
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
For tumors that were FACS sorted, a piece of the tumor was first removed for embedding in OCT and imaging. For carcinomas, skin tissue along the edge of the carcinoma was also removed. Tumors were then finely chopped, washed with PBS, digested in 4mg/mL Collagenase A (Sigma-Aldrich) for 1 hour at 37°C, and then resuspended in 0.25% Trypsin-EDTA (Gibco Life Technologies) and incubated on a shaker at 37°C for 1 hour. Trypsin was neutralized with an equal volume of FBS, and digested tumor filtered through a 40μm filter, pelleted, and resuspended in FACS buffer (2% FBS) for sorting.
Instrument
Flow cytometry experiments were performed on either a FACS Aria II or FACS Aria III cell sorter instrument (BD Biosciences) Software FACS DiVa software was used to collect / analyze flow cytometry data Cell population abundance Relative abundance of cell populations sorted from confetti-labeled tumors varied between sample sets, determined by the expansion of individual clones within a given tumor.
Gating strategy
For all flow cytometry single cell suspension samples, a doublet discrimintation gate was used to exclude doublets from downstream analysis. The confetti model system incorporates the use of 4 fluorophores: RFP (red, positive PE gating), CFP (Blue, positive Pacific Blue gating), YFP (yellow) and GFP (green). As YFP and GFP fluorophores demonstrate overlapping fluorescence and are difficult to distinguish by regular flow cytometry, YFP & GFP+ cells populations were gated together (positive FITC gating). Cell suspensions containing no fluorescent cells were used to determine the gating boundaries between "positive" and "negative" cell populations.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
